Amendments to the Claims

This listing of the claims will replace all prior versions and listing of claims in the subject application.

No amendments were made to the claims.

1-13. (canceled)

14. (previously presented): A method for reducing blood cholesterol levels in a mammal suffering from hypercholesteremia, comprising

administering to the mammal an effective amount of a composition comprising a compound of the following formula:



wherein

R1 = H or C_1-C_6 alkyl;

R2 = H or C_1-C_3 alkyl-X where X = H, OH, Cl, Br, I or F;

R3 = H or C_1-C_3 alkyl;

R4 = H or C_1-C_3 alkyl;

Y1 = CO_2H, $NHSO_2CF_3$, SO_3H, PO_3H_2, OSO_3H, CF_3 or F; and

Z1 = H or OH

or a pharmaceutically acceptable salt thereof.

15. (previously presented): The method according to claim 14, wherein cholesterol levels are reduced in the sera of the blood.

16. (previously presented): The method according to claim 14, wherein cholesterol levels are reduced in the plasma of the blood.

17. (previously presented): A method for reducing blood glucose levels in a mammal suffering from diabetes, comprising

administering to the mammal an effective amount of a composition comprising a compound of the following formula:



wherein

R1 = H or C_1-C_6 alkyl;

R2 = H or C_1-C_3 alkyl-X where X = H, OH, Cl, Br, I or F;

R3 = H or C_1-C_3 alkyl;

R4 = H or C_1-C_3 alkyl;

Y1 = CO_2H, $NHSO_2CF_3$, SO_3H, PO_3H_2, OSO_3H, CF_3 or F; and

Z1 = H or OH

or a pharmaceutically acceptable salt thereof.

18. (previously presented): The method according to claim 17, wherein glucose levels are reduced in the sera of the blood.

19. (previously presented): The method according to claim 17, wherein glucose levels are reduced in the plasma of the blood.

20. (previously presented): The method according to claim 14 or claim 17, wherein the composition is administered in an amount of from about 0.01 mg/kg of body weight/day to about 100 mg/kg of body weight/day.

21. (previously presented): The method according to claim 20, wherein the composition is administered in an amount of from about 0.1 mg/kg of body weight/day to about 25 mg/kg of body weight/day.

22. (previously presented): The method according to claim 14 or claim 17, wherein the composition is administered transdermally, intramuscularly, intravenously, subcutaneously, intranasally, topically or orally.

23. (previously presented): The method according to claim 22, wherein the composition is administered subcutaneously or intravenously.

24. (previously presented): The method according to claim 14 or claim 17, further comprising a pharmaceutically acceptable carrier or excipient.

25. (previously presented): The method according to claim 14 or claim 17, wherein the mammal is a human.

26. (previously presented): The method according to claim 14, wherein the compound is



or a pharmaceutically acceptable salt thereof.

27. (previously presented): The method according to claim 26, wherein the hypercholesteremia is associated with obesity.

28. (previously presented): The method according to claim 26, further comprising a pharmaceutically acceptable carrier or excipient.

29. (previously presented): The method according to claim 17, wherein the compound is



or a pharmaceutically acceptable salt thereof.

30. (previously presented): The method according to claim 29, further comprising a pharmaceutically acceptable carrier or excipient.